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Background: Apolipoprotein E (ApoE) is a multifunctional protein playing both a key role in the metabolism of
cholesterol and triglycerides, and in tissue repair and inflammation. The ApoE gene (19q13.2) has three major
isoforms encoded by ε2, ε3 and ε4 alleles with the ε4 allele associated with hypercholesterolemia and the ε2 allele
with the opposite effect. An inverse relationship between cholesterol levels and gastric cancer (GC) has been
previously reported, although the relationship between apoE genotypes and GC has not been explored so far.
Methods: One hundred and fifty-six gastric cancer cases and 444 hospital controls were genotyped for apoE
polymorphism (ε2, ε3, ε4 alleles). The relationship between GC and putative risk factors was measured using the
adjusted odds ratios (ORs) and their 95% confidence intervals (CIs) from logistic regression analysis. A
gene-environment interaction analysis was performed. The effect of the apoE genotypes on survival from GC was
explored by a Kaplan–Meier analysis and Cox proportional hazard regression model.
Results: Subjects carrying at least one apoE ε2 allele have a significant 60% decrease of GC risk (OR=0.40, 95% CI:
0.19 – 0.84) compared with ε3 homozygotes. No significant interaction emerged between the ε4 or ε2 allele and
environmental exposures, nor ε2 or ε4 alleles affected the median survival times, even after correcting for age,
gender and stadium.
Conclusions: Our study reports for the first time a protective effect of the ε2 allele against GC, that might be partly
attributed to the higher antioxidant properties of ε2 compared with the ε3 or ε4 alleles. Given the study’s sample
size, further studies are required to confirm our findings.
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Apolipoprotein E (ApoE) is a small glycoprotein that
plays a major role in the blood clearance of cholesterol-
rich particles, known as remnant lipoproteins [1]. Be-
sides its well-recognized role in lipid metabolism, ApoE
has been shown to be involved in several pathophysio-
logical processes, including antioxidant and immune ac-
tivities, as well as a modulating effect on angiogenesis,
tumor cell growth and metastasis induction [2]. The
structural gene (19q13.2) for apoE is polymorphic with* Correspondence: sboccia@rm.unicatt.it
1Institute of Hygiene, Università Cattolica del Sacro Cuore, Rome, Italy
3IRCCS San Raffaele Pisana, Rome, Italy
Full list of author information is available at the end of the article
© 2012 De Feo et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the ortwo single nucleotide polymorphisms (SNPs) within the
coding region resulting in three different alleles (ε2, ε3,
ε4) and six apoE genotypes (three homozygotes ε4/ε4,
ε3/ε3 and ε2/ε2, and three heterozygotes ε4/ε3, ε3/ε2,
ε4/ε2), each showing different receptor-binding abilities
[3,4]. A meta-analysis reported a nearly linear relation-
ship between apoE genotypes and the levels of total and
LDL serum cholesterol (LDL-C) when the six genotypes
are ordered as follows: ε2/ε2, ε2/ε3, ε2/ε4, ε3/ε3, ε3/ε4,
ε4/ε4 [5]. In general, compared to the individuals with
the ε3 allele, levels of total and LDL-C tend to be lower
for those with the ε2 allele and higher for ε4 carriers [6].
In the past two decades, cross-sectional and prospective
studies have reported that low serum cholesterol levelsLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Odds ratios (95% CI) for gastric cancer according
to selected variables and their frequency distribution
among 156 gastric cancer cases and 444 controls
Cases Controls OR (95% CI) †
n (%) n (%)
Age (mean ± SD) 67.05±11.33 59.04±16.00
Male gender 82 (53.2) 261 (58.8) 0.50 (0.30-0.83)
Alcohol drinkers
0-6 g/day 60 (40.5) 251 (57.6) 1*
7-29 g/day 71 (48.0) 163 (37.4) 1.84 (1.10- 3.07)
>= 30 g/day 17 (11.5) 22 (5.0) 3.29 (1.36- 7.98)
Smoking status
Never 78 (50.7) 238 (54.2) 1*
Ever 76 (49.3) 201 (45.8) 1.51 (0.94- 2.45)
Pack-years of smoking
0 74 (51.7) 245 (57.0) 1*
1-25 31 (21.7) 111 (25.8) 1.40 (0.78- 2.50)
>25 38 (26.6) 74 (17.2) 1.95 (1.06- 3.60)
Fruit and vegetables intake
High‡ 41 (27.5) 116 (27.2) 1*
Low 108 (72.5) 310 (72.8) 1.18 (0.70- 1.98)
Grilled meat
Low ^ 106 (75.7) 314 (81.1) 1*
High 34 (24.3) 73 (18.9) 1.25 (0.72- 2.15)
Physical activity
Any 29 (18.6) 93 (20.9) 1*
None 127 (81.4) 351 (79.1) 0.81 (0.45- 1.45)
Family history of cancer
No 87 (62.2) 291 (71.2) 1*
Family history of gastric
cancer
10 (7.1) 14 (3.4) 3.14 (1.17- 8.44)
Family history of other
cancer
43 (30.7) 104 (25.4) 1.09 (0.66- 1.81)
ApoE allele frequency
ε3 130 (85.5) 322 (80.1)
ε2 8 (5.3) 39 (9.7)
ε4 14 (9.2) 41 (10.2)
† OR adjusted by age, gender, alcohol consumption (as continuous variable),
packyears of smoking, grilled meat consumption and familiy history of cancer.
* reference category.
‡ at least three portions of fruit and vegetables per day.
^ less than four times/month.
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cially cancer risk [7-10], thus, subjects with low serum
total cholesterol levels are more likely to suffer from
cancer. To date, the exact reason for such finding
remains still unclear. Different explanations can be given
as: (i) this association could theoretically reflect a direct
causal role of cholesterol in cancer etiology, or it be due
(ii) to some confounding factors that cause both low
cholesterol and cancer, or (iii) to ‘reverse causation’, as
low cholesterol levels could simply be the effect of can-
cer rather than the cause [11].
To fully answer the question whether a causal relation-
ship exists between low cholesterol level and cancer, an
alternative epidemiologic approach named “Mendelian
randomization” can be used to overcome the problem of
reverse causality and confounding. According to this ap-
proach, a genetic variation (e.g., apoE) that serves as a
robust proxy for an environmentally modifiable exposure
(e.g., serum cholesterol level) can be used in order to
make causal inferences about a disease [12]. Benn et al.
[13] have recently showed that low LDL-C were robustly
associated with cancer in a large Danish cohort study,
while a reduction in LDL caused by SNPs, including apo
E, was not. By adopting the Mendelian Randomization
approach, Benn concluded that his results are in accord-
ance with those emerged from a cohort of elderly subjects
treated with pravastatin [14] and from the Atherosclerosis
Risk in communities cohort study [15], all suggesting low
LDL are probably due to the preclinical cancer stage and
per se do not cause cancer.
The role of apoE genotypes on gastric cancer (GC) aeti-
ology has not been exlpored so far, as Benn et al. [13] con-
sidered all gastrointestinal cancer with no specific focus on
GC. To date, four cohort studies [10,16-18] explored the re-
lationship between serum cholesterol level and the develop-
ment of GC. Among them, two Japanese cohort studies
[10,18] and a Swedish study [16] reported that low serum
cholesterol levels are independent risk factors for develop-
ing gastric cancer, especially the intestinal histotype. No
association, however, was reported in a large Finnish cohort
study [17]. Since the question of whether hypocholesterole-
mia is a predisposing factor for GC or a preclinical stage of
GC has not been fully solved, our hospital-based case–
control study aims to overcome this issue by directly look-
ing at the relationship between apoE genotypes and GC as
well as their interaction with potential effect modifiers.Results
General characteristics of the study population including
156 GC cases and 444 controls are presented in Table 1.
Alcohol consumption was associated with an increased
GC risk with ORs of 1.84 (95% CI = 1.10–3.07) and 3.29
(95% CI = 1.36–7.98) for moderate and heavy drinkers,respectively. A nearly doubled GC risk (OR=1.95, 95%
CI: 1.06 – 3.60) was detected among individuals smoking
more than 25 pack-years. In addition, family history of
gastric cancer resulted to be associated with an increased
GC risk (OR=3.14, 95% CI: 1.17 – 8.44; Table 1). Table 2
shows the distribution of the six apoE genotypes among
GC cases and controls, with the ε3/ε2 genotype being less
Table 2 Distribution of ApoE polymorphism among gastric cancer cases and controls
Cases ‡ Controls^ All cases Intestinal (n=79) Diffuse (n=57)
n (%) n (%) OR (95% CI)† OR (95% CI)† OR (95% CI)†
ε3/ε3 109 (71.71) 253 (62.94) 1* 1* 1*
ε3/ε2 15 (9.87) 63 (15.67) 0.43 (0.21 -0.91) 0.34 (0.13 – 0.92) 0.57 (0.23 – 1.40)
ε3/ε4 27 (17.76) 75 (18.66) 0.70 (0.37 - 1.30) 0.75 (0.35 – 1.60) 0.64 (0.27 – 1.47)
ε2/ε2 0 (0.00) 5 (1.24) NC NC NC
ε2/ε4 1 (0.66) 5 (1.24) 1.25 (0.10 - 15.10) 2.54 (0.21 – 31.17) NC
ε4/ε4 0 (0.00) 1 (0.25) NC NC NC
ε3/ε2 or ε2/ε2 15 (12.10) 68 (21.18) 0.40 (0.19 - 0.84) 0.31 (0.11 – 0.83) 0.53 (0.21 – 1.30)
ε3/ε4 or ε4/ε4 27 (19.85) 76 (23.10) 0.68 (0.36 - 1.26) 0.71 (0.34 – 1.53) 0.62 (0.27 – 1.43)
‡ Apolipoprotein genotype was measured in 152 cases.
^ Apolipoprotein genotype was measured in 402 controls.
† OR adjusted by age, gender, alcohol consumption (as continuous variable), packyears of smoking, grilled meat consumption and family history of gastric cancer.
* Reference category.
NC: not calculable due to few many values.
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(15.67%).
Frequency of apoE genotypes respected the Hardy-
Weinberg Equilibrium (HWE) in the control group
(p-value > 0.05, data not shown). From the multivariate
analysis, individuals carrying at least one apoE ε2 allele
had a significant 60% decreased risk of GC (OR=0.40, 95%
CI: 0.19 – 0.84) when compared with those homozygous
for the wild-type (ε3/ε3) (Table 2). When results were
stratified according to tumour histology, the significant as-
sociation between apoE ε2 allele carriers and gastric cancer
appeared to be limited to the intestinal type, with an OR of
0.31 (95% CI: 0.11 – 0.83; Table 2). Quality controls showed
100% concordance between Restriction Fragment Length
Polymorphism (RFLP) method and DNA sequencing.
Results of the gene-environment interaction analysis
are presented in Table 3. No statistically significant
interaction emerged between the ε4 or ε2 allele (p-value
for interaction > 0.05), gender, age, alcohol consumption
or fruit and vegetables intake.
Median survival time from gastrectomy was 19 months
with no statistical significant differences for apoE ε2 or ε4
allele carriers (p-value of log-rank test > 0.05), even when
the analysis was restricted to 1 year and 2 years after
surgical intervention (data not shown). Cox regression
analysis showed no significant difference according to
apoE after adjusting for age, gender, and stadium, even
after stratifying by cancer histotype.
Discussion
Our case–control study of 156 gastric cancer cases and
444 hospital-based controls evaluated for the first time
the effect of apoE genotypes and their interactions with
selected demographic and lifestyle factors on the risk of
gastric cancer among an Italian population. According
to our results, the apoE ε2 allele is associated with a 60%
statistically significant decreased risk for GC whencompared with the wild-type ε3 allele. This protective ef-
fect was particularly strong for the intestinal histotype.
We were unable, however, to detect significant interac-
tions between apoE alleles and lifestyle factors. Add-
itionally, apoE genotypes do not appear to influence the
survival time after surgical intervention, even when the
analysis was restricted to the specific tumor histotypes.
Before interpreting our results, some limitations of the
study should be taken into account. Firstly, on the basis
of the prevalence of the apoE alleles in our control
population, this study has a priori 90% power to detect
an OR of 0.40 for the effect of the apoE ε2 allele (at 5%
significance level). The study’s sample size limits the possi-
bility to detect statistically significant gene–environment
interactions, however, we need to increase the sample
size in order to confirm our results. Secondly, data on
serum cholesterol levels are not available in our study
population, even though their utility would be limited in
view of the fact such levels are affected by the cancer
itself.
The effect of apoE genotypes has been previously
investigated in relation to breast, colorectal, biliary tract,
prostate, head and neck cancer, and haematological ma-
lignancies [19-24], with conflicting results. A recently
published Mendelian randomization study addressed the
unsolved question about the causal role of cholesterol in
cancer etiology by examining if some SNPs including
apoE, all linked to lifelong reduced plasma LDL-C, are
causally related to an increased risk of cancer among
two large Danish general population studies [13]. Results
show an inverse relationship between cancer incidence
or mortality and cholesterol levels, while no effect was
demonstrated for the apoE alleles. Even with some lim-
itations on the selected cohort, authors conclude that
there is a substantial lack of causal effect of cholesterol
on cancer risk including gastrointestinal cancers. Ac-
cordingly, the apparent contradiction between results
Table 3 Interactions between apoE genotypes and selected demographic and lifestyle variables on GC risk
Variables Cases Controls Any e2 Cases Controls Any e4
OR (95% CI) † OR (95% CI) †
Gender
Female, e3/e3 51 (34.69) 96 (65.31) 1* 51 (34.69) 96 (65.31) 1*
Female, variant 8 (27.59) 21 (72.41) 0.58 (0.20 – 1.65) 12 (24.00) 38 (76.00) 0.55 (0.23 – 1.32)
Male, e3/e3 57 (26.64) 157 (73.36) 0.48 (0.27 – 0.88) 57 (26.64) 157 (73.36) 0.49 (0.27 - 0.89)
Male, variant 7 (12.96) 47 (87.04) 0.49 (0.11 – 2.18) 14 (26.92) 38 (73.08) 1.52 (0.44 – 5.27)
P value for interaction° 0.347 0.660
Age
<60 years, e3/e3 25 (17.73) 116 (82.27) 1* 25 (17.73) 116 (82.27) 1*
<60 years, variant 4 (12.50) 28 (87.50) 0.35 (0.07 – 1.68) 7 (21.21) 26 (78.79) 0.70 (0.18 – 2.66)
≥60 years, e3/e3 84 (38.01) 137 (61.99) 2.85 (1.53 – 5.28) 84 (38.01) 137 (61.99) 2.84 (1.54 - 5.26)
≥60 years, variant 11 (21.57) 40 (78.43) 1.24 (0.21 – 7.26) 20 (28.57) 50 (71.43) 0.97 (0.21 – 4.36)
P value for interaction 0.807 0.964
Alcohol drinking
Never, e3/e3 45 (24.06) 142 (75.94) 1* 45 (24.06) 142 (75.94) 1*
Never, variant 5 (12.50) 35 (87.50) 0.29 (0.08 – 1.04) 12 (18.18) 54 (81.82) 0.62 (0.28 – 1.37)
Ever, e3/e3 64 (36.57) 111 (63.43) 1.59 (0.88 – 2.86) 64 (36.57) 111 (63.43) 1.46 (0.81 – 2.62)
Ever, variant 10 (23.26) 33 (76.74) 1.78 (0.37 – 8.50) 15 (40.54) 22 (59.46) 1.28 (0.35 – 4.66)
P value for interaction 0.468 0.707
Smoking status
Never, e3/e3 54 (29.03) 132 (70.97) 1* 54 (29.03) 132 (70.97) 1*
Never, variant 8 (20.51) 31 (79.49) 0.48 (0.18 – 1.28) 13 (20.00) 52 (80.00) 0.53 (0.23 – 1.23)
Ever, e3/e3 54 (31.40) 118 (68.60) 1.41 (0.80 – 2.50) 54 (31.40) 118 (68.60) 1.39 (0.79 – 2.45)
Ever, variant 7 (16.28) 36 (83.72) 0.68 (0.15 – 2.98) 13 (36.11) 23 (63.89) 1.98 (0.59 – 6.73)
P value for interaction 0.609 0.271
Fruit and vegetables intake
Low, e3/e3 28 (29.47) 67 (70.53) 1* 28 (29.47) 67 (70.53) 1*
Low ,variant 2 (9.09) 20 (90.91) 0.14 (0.02 – 0.87) 9 (32.14) 19 (67.86) 0.84 (0.28 – 2.49)
High, e3/e3 78 (31.08) 173 (68.92) 1.17 (0.61 – 2.23) 78 (31.08) 173 (68.92) 1.12 (0.59 – 2.13)
High, variant 11 (19.30) 46 (80.70) 2.83 (0.38 – 21.05) 16 (22.86) 54 (77.14) 0.62 (0.16 – 2.37)
P value for interaction 0.309 0.487
† OR adjusted by age, gender, alcohol consumption (as continuous variable), packyears of smoking, grilled meat consumption and familiy history of gastric cancer.
* Reference category.
° By likelihood ratio test.
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respect to apo E, might be indicative of a preclinical can-
cer stage involving the increased uptake of cholesterol
from the blood for the cell growth and proliferation,
thus lowering cholesterolemia prior to the clinical cancer
diagnosis.
As for stomach cancer, two Japanese cohort studies
[10,18] and a Swedish cohort study [16] reported a strong
inverse association between serum cholesterol levels and
risk of gastric cancer. Japanese studies, however, found the
association far less stronger after exclusion of the early
3-year incident cases and advanced cases, thus suggestingthe development of stomach cancer itself tends to lower
total cholesterol levels. To overcome the issues related to
reverse causation or confounding by lifestyle factors, we
decided to clarify the role of cholesterol levels on GC risk
by using a Mendelian randomization approach, namely by
studying directly the effect of the apoE genotypes on a
large series of Italian GC cases and controls. Our results
show a statistically significant 60% decreased risk of GC
associated with the ε2 allele.
Since ε2 carriers have a lower serum cholesterolemia than
non- ε2 carriers, our finding contradicts the previously
reported observation that low serum cholesterol levels
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other functions beside its well-known role in lipid metabol-
ism, that are potentially involved in cancer risk, as it is
involved in tissue repair, inflammatory and immune re-
sponse, cell growth and angiogenesis [2], and shows anti-
oxidant properties [25]. Of importance, ApoE protein has
certain antioxidative properties, with decreasing antioxidant
activity in the order ε2 > ε3 > ε4 alleles [25]. Even if the mo-
lecular mechanisms responsible for the antioxidant proper-
ties of apoE is not clarified yet, a number of studies have
examined the mechanisms through which apoE genotypes
could affect the oxidative status-dependent mediators or
biomarkers of oxidative stress [26-28]. ApoE ε2-carrier
smoking individuals, who are exposed to nicotine, an im-
portant source of oxidative stress, have an almost 30%
higher total antioxidant status compared with apoE
ε3-carriers, measured as the capacity to inhibit the
peroxidase-mediated formation of the 2,2-azino-bis-3-ethyl-
bensthiazoline-6-sulfonic acid (ABTS+) radical, while apoE
ε4 subjects show a 30% increased oxidised LDL [26].
Oxidative stress is given by an imbalance between
increased production of reactive oxygen species and a
significant decrease in the capability of antioxidant func-
tions. The production of peroxides and free radicals
associated with changes in the normal redox state of tis-
sues can induce toxic effects including oxidative DNA
damage that along with hypoxia, and acidosis, might be
greatly involved in the pathogenesis of GC as it can be
considered the cause as well as the consequence of
tumor progression [29,30]. Some evidence showed a
wide magnitude of oxidative stress in GC cases if
compared with healthy individuals, as demonstrated
by elevated levels of lipid peroxidation products and
depletion of enzymatic and non-enzymatic antioxi-
dants [31,32]. In view of all these findings, the
results of our study, which reports a protective effect
of the apoE ε2 allele on GC, might be explained by
the improved antioxidant properties of ε2 allele
compared with the ε3 or ε4 alleles, and this evidence
can be especially true for GC, whose pathogenesis is
strongly affected by smoking-related oxidative stress
[33]. If our model holds true, we would expect an
interaction between apoE ε2 allele and smoking sta-
tus, however the limited power of our interaction
analysis may have obscured it.
Conclusions
In conclusion, our study provides for the first time evi-
dence of a possible protective effect of the ε2 allele
against GC. Further studies are required to confirm our
results and to figure out if the protective effect is
mediated through lowered cholesterol level or better
antioxidant properties.Methods
Study population
The study subjects were selected according to a case–
control study design as previously described [34-36].
Briefly, cases were consecutive primary gastric adenocar-
cinoma patients, with histological confirmation, who
underwent a curative gastrectomy in the "A. Gemelli"
teaching hospital during the period 2002–2010. Controls
were selected from cancer-free patients, with a broad
range of diagnoses, admitted to the same hospital during
the identical time period.
In closer details, about 50% of our control population
is made of blood donors while the other half is made
of patients undergoing surgical interventions as laparo-
scopic cholecystectomy or appendicitis or inguinal
hernia and a smaller portion of patients affected by chronic
diseases as hypertension or Chronic Obstructive Pulmonary
Disease (COPD) undergoing periodical check-up.
All subjects were Caucasians born in Italy. The study
sample size comprised 156 cases and 444 controls, with
a participation rate of 98% among cases and 93% among
controls. According to Lauren classification, the majority
(58.1%) of gastric cancer cases were intestinal [37]. The
tumours were located in the antrum (44.5%), in the cor-
pus (14.8%), in the antrum/corpus (21.1%), in the cardia
(3.1%), stumps (5.5%), in the fundum (1.6%), in the car-
dia/corpus (6.3%) and the entire stomach (3.1%). Based
on the cytological and architectural atypisms, as well as
the histo-pathological reports [38], patients’ tumours
were classified accordingly: 70.0 % scarcely differentiated
(G3), 27.6 % moderately differentiated (G2), 3.4 % well-
differentiated (G1), while 51.7% were staged I-II and
48.3% staged III-IV.
Written informed consent was obtained from all study
subjects, after which each subject provided a venous
blood sample that was collected into EDTA-coated
tubes. This study was performed according to the Dec-
laration of Helsinki and was approved by the ethics com-
mittee of the Università Cattolica del Sacro Cuore.
Genotyping
DNA was extracted from the peripheral blood lympho-
cytes, and genotyping of apoE was performed using
Restriction Fragment Length Polymorphism (RFLP).
Briefly, 20ng of genomic DNA amplified using oligo-
nucleotide primers 5’-TCC AAG GAG CTG CAG GCG
GCG CA-3’ and 5’-GCC CCG GCC TGG TAC ACT
GCC A-3’. Reactions were denatured for 3 minutes at
95°C, followed by 35 two-step cycles consisting of 10
seconds at 95°C then 10 seconds at 66°C. After the
cycles were completed a final extension of 5 minutes at
95°C was performed. A 10 μl aliquot of each RFLP prod-
uct was digested with 5 U of AflIII and a separate 10 μl
aliquot was digested with 5 U of HaeII. Both apoE ε2
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of 50 and 168 bp, while the apoE ε4 allele remains uncut
at 218 bp. Using HaeII, both apoE ε3and apoE ε4 alleles
yield products of 23 and 195 bp, while the apoE ε2 allele
remains uncut at 218 bp. The six possible genotypes
were assigned by analyzing the patterns produced by the
restriction digest. As for the quality controls, 5% of the
samples were also sequenced, with standard DNA sam-
ples for each apoE genotype sent by Seripa et al. [39].
Data Collection
Cases and controls were interviewed by trained medical
doctors using a structured questionnaire to collect infor-
mation on demographic data, cigarette smoking, drinking
history, dietary habits, physical activity and family history
of cancer with a special focus on gastric cancer. Partici-
pants were asked to focus on the year prior to diagnosis
(for controls the year prior to the interview date) when
answering questions regarding lifestyle habits. Smoking
status was categorized as never and ever-smokers (includ-
ing both current and former smokers). Pack-years were
calculated as years smoked multiplied by the current num-
ber (or previous number, for those who had quit) of cigar-
ettes smoked per day divided by 20.
Fruit and vegetables intake was categorized as high if
at least three portions of fruit and vegetables were con-
sumed daily while grilled meat intake was defined as low
if the consumption was less than 4 times/month. Family
history of cancer referred to parents, siblings and off-
spring. Data concerning previous Helicobacter pylori in-
fection were available only for gastric cancer cases. The
response rate for completing the interview was 92% for
cases and 97% for controls, with the exception of data
relating to grilled meat intake (unknown in 10% of cases
and 12.8% of controls) and the family history of cancer
(unknown in 10% of cases and 8% of controls).
Statistical analysis
The relationship between gastric cancer and putative
risk factors were measured using the adjusted odds
ratios (ORs) and their 95% confidence interval (CI)
derived from logistic regression analysis using STATA
software (version 10.0). Possible risk factors were consid-
ered to be confounders if the addition of that variable to
the model changed the OR by 10% or more, and once a
confounder of any estimated main effect was identified,
it was kept in all models. Based on these criteria, we
controlled for age, gender, alcohol and grilled meat con-
sumption, cigarette smoking (pack-years) and family his-
tory of gastric cancer. A χ2-test of Hardy-Weinberg
Equilibrium (HWE) for the three apoE alleles was per-
formed among controls. In order to examine if the effect
of the selected polymorphisms was modified by some
environmental exposures, a stratified logistic regressionanalysis was performed, adjusting for the confounders
previously identified. A gene-environment interaction
analysis was performed by using those carrying the
homozygous wild-type genotype (ε3/ε3 related to the
apoE ε3 isoform) as the reference group. In this analysis,
the genotypes were categorized as follows: presence of at
least one apoE ε2 allele or presence of at least one apoE
ε4 allele (the genotype ε2/ε4 was not included in either
category), providing the other two apoE isoforms (apo
E2 and apo E4).
In this analysis, age was categorized binomially (< 60
and ≥ 60 years old), smoking status was considered as
ever/never cigarette smokers, and alcohol consumption
as drinkers/non-drinkers (the latter including individuals
whose alcohol intake was less than 7 g/day). In order to
test for interaction between two exposure variables, the
likelihood ratio test was used, with the individuals
homozygous for wild-type genotype (ε3/ε3) and not
exposed to the variables of interest used as the reference
group.
Overall survival curves were calculated by the Kaplan-
Meier product limit method from the date of diagnosis
until death. If a patient was not dead, survival was cen-
sored at the time of the last visit. The log rank test was
used to assess differences between subgroups. The risk
of death related to ApoE isoforms was estimated by
Cox's proportional hazards model. Hazard ratios (HR)
were adjusted for age, gender, and stadium, with the
wild-type genotype (ε3/ε3) as the reference group. In
addition, analyses were stratified according to cancer
histotype (intestinal/diffuse).Abbreviations
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